Evaluation of inhibitor antibody in hemophiliaA population.

BACKGROUND Inhibitor antibody to exogenous Factor VIII (FVIII) is a major complication of hemophilia treatment. This study was conducted to determine the prevalence of inhibitor antibody directed against FVIII. METHODS From May 2010 to May 2011, 52 patients with severe hemophilia A admitted in Amirkola Children's Hospital were evaluated. Those who had abnormal mixing study, antibody against FVIII were measured. Data were collected and analyzed. RESULTS The age range of the patients was 4-60 years. The inhibitor antibody was seen in 9 (17.3%) patients. The mean age of patients with inhibitor at the time of diagnosis was 10.22 years (ranged 4-31 years). Old patients had more hemarthrosis than young patients. The mean level of inhibitor antibody was 8.47 Bethesda unit (ranged 2.3-29). Six patients had inhibitor antibody level ≥5 Bethesda unit and three patients had inhibitor antibody level <5 Bethesda unit. CONCLUSION This study showed that the prevalence of inhibitor antibodies in young patients is more than the old patients.